Co-Authors
This is a "connection" page, showing publications co-authored by Mark J. Ratain and Richard A. Larson.
Connection Strength
0.637
-
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996 Jan; 14(1):188-95.
Score: 0.135
-
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
Score: 0.126
-
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
Score: 0.066
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.062
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.031
-
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
Score: 0.031
-
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38.
Score: 0.031
-
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol. 1992 Nov; 10(11):1821.
Score: 0.027
-
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1992 Apr 01; 79(7):1892-3.
Score: 0.026
-
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. J Clin Oncol. 2008 May 20; 26(15_suppl):7057.
Score: 0.020
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.020
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.019
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.019
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.016
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.008